IL326276A - צורות גליקו-מהונדסות של נוגדנים ror1 ושיטות שימוש - Google Patents

צורות גליקו-מהונדסות של נוגדנים ror1 ושיטות שימוש

Info

Publication number
IL326276A
IL326276A IL326276A IL32627626A IL326276A IL 326276 A IL326276 A IL 326276A IL 326276 A IL326276 A IL 326276A IL 32627626 A IL32627626 A IL 32627626A IL 326276 A IL326276 A IL 326276A
Authority
IL
Israel
Prior art keywords
methods
ror1 antibodies
glycoengineered forms
glycoengineered
forms
Prior art date
Application number
IL326276A
Other languages
English (en)
Original Assignee
Ho Ola Therapeutics Inc
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ho Ola Therapeutics Inc, Univ California filed Critical Ho Ola Therapeutics Inc
Publication of IL326276A publication Critical patent/IL326276A/he

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
IL326276A 2023-08-01 2024-07-31 צורות גליקו-מהונדסות של נוגדנים ror1 ושיטות שימוש IL326276A (he)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202363517088P 2023-08-01 2023-08-01
US202363607456P 2023-12-07 2023-12-07
PCT/US2024/040391 WO2025029920A1 (en) 2023-08-01 2024-07-31 Glycoengineered forms of ror1 antibodies and methods of use

Publications (1)

Publication Number Publication Date
IL326276A true IL326276A (he) 2026-04-01

Family

ID=94396006

Family Applications (1)

Application Number Title Priority Date Filing Date
IL326276A IL326276A (he) 2023-08-01 2024-07-31 צורות גליקו-מהונדסות של נוגדנים ror1 ושיטות שימוש

Country Status (5)

Country Link
KR (1) KR20260048599A (he)
CN (1) CN121969650A (he)
AU (1) AU2024316152A1 (he)
IL (1) IL326276A (he)
WO (1) WO2025029920A1 (he)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7317091B2 (en) * 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20120282177A1 (en) * 2009-11-02 2012-11-08 Christian Rohlff ROR1 as Therapeutic and Diagnostic Target
EP3219731A1 (en) * 2010-10-01 2017-09-20 Oxford BioTherapeutics Ltd Anti-ror1 antibodies
WO2016094873A2 (en) * 2014-12-12 2016-06-16 Emergent Product Development Seattle, Llc Receptor tyrosine kinase-like orphan receptor 1 binding proteins and related compositions and methods
WO2016187220A2 (en) * 2015-05-18 2016-11-24 Five Prime Therapeutics, Inc. Anti-ror1 antibodies
CA3067829A1 (en) * 2017-06-23 2018-12-27 VelosBio Inc. Ror1 antibody immunoconjugates

Also Published As

Publication number Publication date
WO2025029920A1 (en) 2025-02-06
AU2024316152A1 (en) 2026-02-26
CN121969650A (zh) 2026-05-01
KR20260048599A (ko) 2026-04-10

Similar Documents

Publication Publication Date Title
GB202019709D0 (en) Anti-Coronavirus antibodies and methods of use
PT4267105T (pt) Composições de anticorpos e métodos de utilização das mesmas
IL316368A (he) נוגדנים אנטי- tl1a ושיטות לשימוש בהם
PT4200018T (pt) Anticorpos anti-par-2 e métodos de uso dos mesmos
IL315845A (he) נוגדנים אנטי-דקטין-1 ושיטות לשימוש בהם
IL298668B1 (he) נוגדנים נגד cd200r1 ושיטות לשימוש בהם
IL319674A (he) נוגדן אנטי il-1r3 אנושי ושיטות שימוש
IL318694A (he) נוגדנים כנגד ccr8 ושיטות לשימוש בהם
IL317690A (he) נוגדנים אנטי- gpnmbושיטות לשימוש בהם
CA3266931A1 (en) ANTI-NAPI2B ANTIBODIES AND METHODS OF USE
IL300104A (he) נוגדן ספציפי למוסין-1 ושיטות לשימוש בו
AU2021352981A9 (en) Anti-cd94 antibodies and methods of use thereof
CA3300311A1 (en) Glycoengineered forms of ror1 antibodies and methods of use
IL325937A (he) נוגדנים המועברים על ידי aav ושיטות לשימוש בהם
IL318357A (he) נוגדני anti-il27r ושיטות השימוש בהם
IL316700A (he) נוגדני anti-bmp9 ושיטות השימוש בהם
IL316894A (he) נוגדני anti-tnfr2 ושיטות השימוש בהם
GB202204813D0 (en) Human monoclonal antibodies and methods of use thereof
GB202204736D0 (en) Human monoclonal antibodies and methods of use thereof
HK40110072A (en) Antagonist anti-npr1 antibodies and methods of use thereof
IL308260A (he) נוגדנים נגד טיגיט ודרכי השימוש בהם
HK40095257A (en) Antibody specific for mucin-1 and methods of use thereof
HK40085995A (en) Anti-gipr antibody and methods of use thereof
HK40115022A (en) Anti-cd300lb antibodies and methods of use thereof
HK40108519A (en) Anti-siglec-6 antibodies and methods of use thereof